Surgery or radiotherapy is the gold standard treatment for low- to intermediate-risk localized prostate cancer patients. Still, the side effects of the treatment and possible patient comorbidities might hamper patients from allowing these kinds of approaches.
SoracteLite is an innovative and micro- invasive treatment for BPH. It is a non- surgical procedure which, by exploiting laser energy, obtains a significant reduction in the volume of the prostate consequently freeing up the urethral channel from the compressive processes that obstruct normal urinary flow.
Platelet-rich plasma (PRP) therapy is a natural treatment which reinjects platelets and growth factors into your body, which have been gathered from a sample of your own blood. This produces a healing response in the body to repair and rejuvenate an area.
Platelet-rich plasma (PRP) therapy is a natural treatment that reinjects platelets and growth factors into your body, which have been gathered from a sample of your own blood. This produces a healing response in the body to repair and rejuvenate an area.
The Vantage Urologic Institute is pleased to announce the launch of our free Men’s Health Screening Program. Free screenings will be offered daily Monday through Saturday.
Vantage Urologic Institute is proud to provide our patients with a safe and effective way to control discomfort and anxiety during urologic diagnostic and therapeutic procedures: PRO-NOX™ Nitrous Oxide Delivery System.
Rezūm is a treatment for BPH that can be performed in a clinic or out-patient setting. Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow,
The proven, minimally invasive treatment that fills the gap between prescription medications and more invasive surgical procedures.
Most men think of estrogen as exclusively a female hormone, but men also produce it. In fact, testosterone is the precursor of estradiol, an estrogen, and the primary female sex hormone. Testosterone is converted into estradiol via the aromatase enzyme.
A myriad of molecular-based risk assessment tests derived from serum, urine, and tissue have emerged to improve the specificity for detection and stratification of clinically significant prostate cancer.